Day One Biopharmaceuticals, Inc.
DAWNNASDAQHealthcare
$21.53
+$0.00(+0.00%)
Market Cap$2.2B
P/E Ratio—
52W High$21.53
52W Low$5.635
Day One Biopharmaceuticals, Inc. (DAWN) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DAWN · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.11B) | ($0.10B) | ($0.19B) | ($0.14B) | ($0.07B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.04B | $0.05B | $0.04B | $0.03B | $0.01B |
| Change in Working Capital | ($0.03B) | $0.03B | $0.01B | $0.01B | $0.00B |
| Net Cash from Operations | ($0.10B) | ($0.08B) | ($0.15B) | ($0.11B) | ($0.05B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.01B) |
| Purchases of Investments | ($0.70B) | ($0.66B) | ($0.44B) | ($0.39B) | $0.00B |
| Sales of Investments | $0.87B | $0.39B | $0.58B | $0.14B | $0.00B |
| Net Cash from Investing | $0.17B | ($0.23B) | $0.13B | ($0.26B) | ($0.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.00B | $0.20B | $0.16B | $0.17B | $0.30B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.10B) | ($0.08B) | ($0.15B) | ($0.11B) | ($0.06B) |
| FCF Margin %(computed) | -65.80% | -61.21% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Day One Biopharmaceuticals, Inc. data
About Day One Biopharmaceuticals, Inc. (DAWN) Cash Flow Statement
Day One Biopharmaceuticals, Inc. generated operating cash flow of ($0.10B) and free cash flow of ($0.10B) for 2025 — a FCF margin of -65.80%. Capital expenditure was ($0.00B).
Frequently asked questions
DAWN · 4 questionsDay One Biopharmaceuticals, Inc. generated free cash flow of ($0.10B) for 2025, down 29.6% year-over-year.
DAWN free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10